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Abstract
Background: Chronic immune sensory polyradiculopathy (CISP) identifies a progressive acquired peripheral dysimmune
neuropathy recognized as a chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) variant. We describe a
young woman with a thirteen-year history of CISP with a belated variable response to intravenous immunoglobulin
(IVIG) and an almost erratic anticipation of symptoms between IVIG cycles. The association of IVIG and corticosteroids,
immunosuppressants, plasmapheresis, did not lead to clinical improvement and was characterized by significant side
effects. We evaluated a combined clinical and somatosensory evoked potentials (SSEPs) approach aimed to identify
possible predictive parameters concerning the effect and duration of each IVIG administration. Neurologic disability was
evaluated using INCAT - Overall Disability Sum Score (INCAT-ODSS).
Case presentation: A 30-year-old woman presented on 2004 for the subacute onset of asymmetric paresthesias in the
lower limbs over the previous six months. The symptoms had been relapsing-remitting during the first four months,
followed by a slow progression, resulting in limbs ataxia and a progressive gait disturbance requiring Canadian crutches.
Motor and sensory nerve conduction studies and electromyographic evaluation were into normal limits. Median SSEPs
were normal, while tibial SSEPs were characterised by the bilateral absence of both lumbar and cortical responses.
Cerebrospinal fluid detected an increased protein concentration, while spinal MRI showed a pronounced thickening of
the sacral nerve roots, together with a tube-shaped enlargement. These findings led to the diagnosis of CISP and the
patient was treated with IVIG reaching a stable remission over the following 9 years. In early 2014, the patient began to
show a variable response to treatment with erratic anticipation of sensory disturbances, and a more pronounced walking
disability: corticosteroids, plasmapheresis, mycophenolate mofetil and cyclophosphamide were uneffective and
burdened by relevant side effects. To better assess the response to IVIG in terms of time-effect, consistency and duration,
we have combined a scheduled clinical and SSEPs evaluation during and after each IVIG cycle.
Conclusions: The correlation between the neurophysiological data and the INCAT-ODSS scores has allowed the
modulation of IVIG cycles with a significant reduction of the clinical fluctuations and disability. SSEPs may therefore
represent an useful and recommended additional aid for the treatment schedule of this rare clinical form.
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Background
The term chronic inflammatory demyelinating polyradi-
culoneuropathy (CIDP) identifies a chronic-progressive
acquired peripheral neuropathy. The clinical picture is
characterised by sensorimotor signs and symptoms due
to an inflammatory demyelinating process that is dysim-
mune in nature [1, 2].
The symptoms usually develop over a period of at least
8 weeks and are usually characterised by muscle weak-
ness associated with sensory disturbances (paresthesia,
dysesthesia, and hypoesthesia in some cases), moderate
muscle wasting and areflexia. The weakness, distal and
symmetric at onset, gradually tends to involve the prox-
imal limb’s segments, resulting in a progressive disability
in walking, climbing stairs and in all movements against
gravity, while the cranial district is usually spared. Occa-
sionally, a postural tremor may be present, usually due
to muscle weakness [1, 2].
Several CIDP variants have been described and classified
as “atypical forms” in the diagnostic criteria of the Euro-
pean Federation of Neurological Societies/Peripheral Nerve
Society (EFNS/PNS) [3]. Chronic immune sensory polyra-
diculopathy (CISP) is an almost rare form: paresthesia,
pain, numbness, and ataxia represent the main symptoms
with an asymmetric distribution at onset and progression
to a distal symmetric pattern [4]. Nerve conduction studies
are normal and the diagnosis of a demyelinating process is
revealed by prolonged somatosensory evoked potentials
(SSEPs) [5–7]. We describe the results of a combined clin-
ical (INCAT - Overall Disability Sum Score - ODSS) and
neurophysiological (SSEPs) approach we adopted to assess
the effect and duration of response to intravenous im-
munoglobulin (IVIG) treatment in a long-lasting case of
CISP with belated variable response to treatment and er-
ratic anticipation of sensory symptoms [8].
Case presentation
An otherwise healthy 30-year-old woman presented on
2004 for the subacute onset of asymmetric paresthesias
in the lower limbs over the previous six months. The
symptoms had been relapsing-remitting during the first
four months, followed by a slow progression that re-
sulted in limbs ataxia and a progressive gait disturbance
requiring Canadian crutches (ODSS: 4). Routine blood
examinations, vitamins E and B12, folate, lipid profile,
serum protein electrophoresis with immunofixation,
Fig. 1 Spinal MRI study. MR coronal STIR (a), sagittal STIR (b) and T2-weighted sagittal (c) images of the cauda equina showing marked thickening
of the nerve roots together with a tube-shaped enlargement. (R = right; L = left; A = anterior; P = posterior)
Fig. 2 Sural nerve biopsy. Cross section of plastic embedded left
sural nerve stained with Toluidin blue showing slight axonal
impairment without inflammatory infiltrate, a minimal reduction in
myelinated fibers density with some isolated aspects of chronic
(cluster) reinnervation (white arrow) and sporadic fibers in Wallerian
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ceruloplasmin, angiotensin-1-converting enzyme, thyroid
function including anti-thyroid antibodies were normal.
Laboratory research for neoplastic, rheumatic, celiac and
venereal disease, as well as myelin associated glycoprotein,
sulfatide and anti-peripheral nerve antibodies showed nor-
mal values.
Motor and sensory nerve conduction studies (median,
ulnar, common peroneal, tibial, sural nerves) and elec-
tromyographic evaluation (extensor digitorum brevis, tibi-
alis anterior, quadriceps femoris, first dorsal interosseous,
extensor digitorum communis, deltoid, L4-L5 and D9
paraspinal muscles) were into normal limits, with the ex-
ception of a bilateral mild elongation of the tibial F-waves
latencies (< 15% of the upper normal limit). Median SSEPs
were normal, while tibial SSEPs were characterised by the
bilateral absence of both lumbar (N22) and cortical (P40)
responses.
A lumbar puncture detected clear cerebrospinal fluid
(CSF) without cellularity, a normal glucose level (52 mg/dl)
and an increased protein concentration of 128 mg/dl
(NV < 50 mg/dl).
Spinal MRI showed a pronounced thickening of the sa-
cral nerve roots, together with a tube-shaped enlargement
(Fig. 1).
A left sural nerve biopsy was performed, showing slight
axonal impairment without inflammatory infiltrate, a
Fig. 3 Superimposed graphs of the daily ODSS and the longitudinal trend of tibial SSEPs (N22 and P40 latencies) recorded every 7 days over a
period of 16 consecutive weeks. The bold lines below the horizontal axis refer to each cycle of IVIG scheduled every 28 days. Note the large P40
latencies fluctuations significantly correlated to the highest ODSS values
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minimal reduction in myelinated fibre density with some
isolated aspects of chronic (cluster) reinnervation, and
sporadic fibres in Wallerian degeneration (Fig. 2).
These findings led to the diagnosis of CISP and the pa-
tient was treated with a high dose course of methylpred-
nisolone (500 mg/day for 8 consecutive days), without
significant effects on ataxia and on walking disability
(ODSS: 4–5). As a second step, ten days after high dose
steroid course, she was treated with IVIG (0.4 g/kg per
day, for 5 consecutive days) every 4 weeks: vibration
sense and joint position began to improve after the third
IVIG-dose, with a marked reduction of the ataxic pat-
tern, and an almost normal walking ability was achieved
on the tenth day (ODSS: 1–2). This regimen has ensured
a prolonged and stable remission over the following
9 years with an ODSS of 0–1.
In early 2014, the patient started to have symptom fluc-
tuations, a variable response to treatment with erratic an-
ticipation of sensory disturbances, and a more pronounced
walking disability (ODSS: 2–4): she was treated with
plasmapheresis (3 a week cycles for 3 weeks without bene-
fit), mycophenolate mofetil (500 mg per day, discontinued
after 4 weeks for relevant side effects - diarrhoea and
vomiting), and cyclophosphamide (100 mg per day added
to IVIG, maintained for 5 months, and then discontinued
because of loss of weight and leukopenia). The patient was
therefore subsequently kept only on IVIG therapy. To bet-
ter assess the response to IVIG in terms of time-effect,
consistency and duration, we have combined a scheduled
clinical (ODSS scale) and SSEPs evaluation during and
after each IVIG cycle.
Materials and methods
Basing on the patient’s IVIG regimen (5 consecutive days
every 4 weeks) we have assessed bilaterally tibial and
median SSEPs together with nerve conduction studies
(NCS) at the first day of each IVIG administration and
after 7, 14 and 21 days for 16 consecutive weeks; the
neurologic disability was recorded daily using the
INCAT-ODSS [8].
Obtained the informed consent, NCS and SSEPs have
been performed at a skin temperature of 32 °C, following
the standard guidelines [9–11].
For each registration, we have considered the “peak la-
tency” (ms) and “peak-to-peak amplitude” (μV) for N9,
N13, N20, N22, and P40 responses, with any faulty re-
cordings being marked as “0”.
All collected data underwent statistical analysis, con-
ducted with Statistical Package for Social Science -Version
19.0 (SPSS Inc), by setting the statistical significance level
at 0.05. For descriptive statistics, we presented the data as
the percentage distributions for categorical variables and
as the means with standard deviations for continuous
variables. Frequency distributions were compared by
the chi-square test, and means were compared by the
Kruskal-Wallis H-test for continuous variables. Correla-
tions were assessed by the Spearman’s regression analysis.
Results
The baseline evaluation of the SSEPs data showed a wide
fluctuation of P40 latencies, ranging from 0 (41.1% of
cases after right-side stimulation; 29.4% after left-side
stimulation) to 55 ms for both sides (NV ≤ 44.2 ms); these
values were greater than 6 standard deviations (SDs) com-
pared with our normative data. For the N22 component,
the absence of the evoked response has been documented
in 82.3% of cases after right-side stimulation and in 64.7%
after left-side stimulation. At the same time, ODSS values
were quantified in the range of major disabilities (4–6) in
61.4% (70/114) of the total recordings, and with scores
5–6 (severe disability) in 35% (40/114) (Fig. 3-4). The
amplitudes of the evoked responses (if present) were
consistently 2 SDs under the normative values, with
marked chronodispersion. The data derived from the upper
Fig. 4 Example of SSEPs pattern recorded at the 28th-day control after an IVIG cycle. Upper traces: SSEPs from median nerve stimulation show
normal responses. Lower traces: SSEPs from tibial nerve stimulation show absence of both the peripheral and cortical responses
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limbs stimulation have instead shown stable and normal
values for all the evoked components (N9, N13, N20), as
for the central conduction time (Fig. 4).
The statistical correlation between neurophysiological
data and the daily ODSS scores has shown a mean clin-
ical worsening 16 ± 3.1 days after IVIG treatment, while
the longitudinal analysis of ODSS scores, compared to
the frequency of IVIG cycles (5 consecutive days every
4 weeks), has shown, for each cycles, a significant clin-
ical worsening (ataxia) respectively at days 17, 12, 19
and 18 (Fig. 3). The isolated record on day 12 has been
observed in the context of a minor infectious event of
the upper airways which may contribute to a negative
modulation of the dysimmune pattern. Thus excluding
this confounding data, the mean clinical deterioration
was estimated to occur on the eighteenth day. As a con-
sequence, we have planned 5 consecutive IVIG doses
every 18 days, repeating the neurophysiological monitor-
ing at the first day of IVIG infusion, after 7 and 14 days
for 13 consecutive registrations, together with a daily
evaluation of the ODSS.
The statistical analysis of the new data collection has
shown, unlike the baseline assessments, a) an always re-
liable N22 and P40 responses; b) a significant reduction
Fig. 5 Superimposed graphs of the daily ODSS and the longitudinal trend of tibial SSEPs (N22 and P40 latencies) recorded the first day of each
IVIG administration and after 7–14 days for 13 consecutive recordings. The bold lines below the horizontal axis refer to each cycle of IVIG
scheduled every 18 days. Note the relevant stabilization of P40/N22 latencies and the reduction of ODSS values
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of P40 and N22 latencies (p < 0.04) with a mean values
of 45.6 ± 3.9 ms (range: 42.0–57.0) in the right-side,
46.6 ± 3.4 ms (range: 42.4–54.7) in the left side for P40,
and 24.0 ± 2.0 ms (range: 20.7–27.4) in the right side,
25.6 ± 1.58 ms (range: 22.8–28.4) in the left side for
N22, respectively. Note that the highest scores (57 ms
for P40, and 27.4 ms for N22) have been recorded only
once during the whole neurophysiological monitoring
(Figs. 5 and 6). The ODSS scores were in the range 0–2
(moderate or absent disability) in 77.7% (56/72) of the
total recordings, and with score 3 (“requires unilateral
support to walk 10 meters - stick, single crutch, one
arm”) in only 15.2% (11/72) (Fig. 5). When compared to
baseline results, the new data are much more homoge-
neous, as confirmed by the significant reduction of SDs
from the average values (1–1.5 SDs).
The time course analysis of P40 latencies (from the
first day of IVIG infusion to the beginning of the subse-
quent cycle) showed an improving trend, for the right
side, between the first and the second week (from a
mean value of 45.5 ± 0.71 ms to 42.7 ± 0.9 ms), followed
by a worsening trend between the second and third
week (mean value: 48,65 ± 6,06 ms). These trends were
found to be statistically significant (p = 0.046 - Kruskal-
Wallis H test), and similar results have been detected on
the left side, reaching the threshold of statistical signifi-
cance (p = 0.051). The pejorative and ameliorative trend
is also confirmed by the changes in ODSS scores, from a
mean value of 2.6 in the first week (discrete disability),
to 0.8 in the second week (minimal disability), and fi-
nally equal to 1.8 in the third week (p < 0.001 - Kruskal-
Wallis H test). No statistical correlation has been found
considering N22 and P40 amplitudes.
Nerve conduction studies were consistently within the
normative values, including F-waves, without statistical
correlation between clinical exacerbations or improve-
ment after each IVIG protocol.
Discussion and conclusion
An inflammatory radiculoneuropathy with the predom-
inant involvement of the dorsal roots has been originally
described by Sinnreich as a cause of sensory ataxia,
introducing the term of chronic immune sensory poly-
radiculopathy (CISP). All the patients had gait ataxia,
large-fibre sensory impairment, paraesthesias, an high
CSF protein level, a completely normal motor and sen-
sory nerve conduction studies, and abnormal SSEPs as
a specific hallmark, as in our case [12–15]. Moreover,
the neuropathological findings were also not specific
for a peripheral demyelinating process, and ruled out
the presence of an inflammatory infiltrate [16].
According to the EFNS/PNS guidelines CISP is clinic-
ally classified within the subgroup of atypical-CIDP, but
the diagnosis is feasible only by considering several
“supportive criteria”, and it cannot be further charac-
terised in terms of “definite”, “probable” or “possible”
since electrodiagnostic criteria do not include SSEPs,
which represent the more sensitive diagnostic tool [3, 17].
Several authors have indeed recently underlined the
diagnostic properties and utility of SSEPs in evaluating
CIDP patients [18–21].
In the present case, considering clinical fluctuations and
the erratic response to IVIG treatment, we have planned a
neurophysiological approach (SSEPs) together with the
daily ODSS record, not only for a diagnostic confirmation,
but also to search possible correlations between neuro-
physiological and clinical data potentially exploitable for
therapeutic purposes. Consider also that we often modu-
late “empirically” the IVIG cycles following the criterion
of the clinical worsening, as well as the choice of other
Fig. 6 Example of SSEPs pattern recorded at the 18th-day control after an IVIG cycle. Upper traces: SSEPs from median nerve stimulation show
normal responses. Lower traces: SSEPs from tibial nerve stimulation show the presence of both the peripheral (N22) and cortical (P40) response,
although the latter with increased latency
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therapeutic measures (corticosteroids, immunosuppressants,
plasmapheresis) [22–24].
Our data, although derived from a single case, show a
close correlation between serial SSEPs and ODSS scores,
thus contributing to the assessment of the effect and
duration of IVIG administration and, accordingly, into
the modulation of the frequency of IVIG intake, allowing
the patient to reduce both clinical fluctuations and dis-
ability with any further significant relapse. In addition,
the new therapeutic regimen, scheduled according to the
neurophysiological evidences, has enabled a significant
improvement of the ODSS global average score from
3.85 to 1.83.
We agree with some previous evidences about the
non-localizing property of tibial SSEPs in the demyelin-
ating process but, as shown in this case, they may be an
useful supportive aid to establish the more appropriate
therapeutic program faithfully reproducing the evolution
of the clinical picture [4, 18, 21]. Undoubtedly, none of
the two resources (SSEPs and ODSS) reaches an absolute
diagnostic power, but we recommend their execution and
integration in such rare and selective clinical forms.
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